latozinemab (AL001) — NDA/BLA submission
2026
Pending the trial's outcome, the companies are preparing for potential Biologics License Application (BLA) and Marketing Authorization Application (MAA) submissions in 2026.Source filing
ALEC biotech catalysts & pipeline
ALECTOR INC · Data as of 2026-09-08
Upcoming catalysts
nivisnebart (AL101/GSK4527226) — Regulatory decision
2026
Trial completion is expected in 2026.Source filing
AL037/AL137 — IND submission
in Q1 2027
The company is targeting an IND submission in Q1 2027.Source filing
AL050 — IND submission
2027
The company is targeting submission of an IND application in 2027.Source filing
AL137 — IND submission
Q1 2027
The company is targeting an IND submission in Q1 2027 and first-in-human dosing in Australia no later than April 2027.Source filing